Skip to main content
. Author manuscript; available in PMC: 2010 Mar 5.
Published in final edited form as: Mol Cell Endocrinol. 2008 Nov 5;300(1-2):115–120. doi: 10.1016/j.mce.2008.10.032

Figure 1.

Figure 1

Representative western immunoblot of aromatase (CYP19) protein in H295 cells after treatment (6 h) with VIP (100 nM) or forskolin (10 μM). Lane 1: CHO-K1 cells transfected with human CYP19 cDNA (25 μg protein); lane 2: non-transfected CHO-K1 cells (25 μg protein); lane 3: untreated (Ctrl) H295 cells (25 μg protein); lane 4: VIP-treated H95 cells (25 μg protein); lane 5: Forskolin (Fsk)-treated H295 cells (25 μg protein).